Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) - Clinical Trial Optional

The summary for the Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) - Clinical Trial Optional grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) - Clinical Trial Optional: The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
Federal Grant Title: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44) - Clinical Trial Optional
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education Health Income Security and Social Services
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-18-541
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.121, 93.213, 93.242, 93.273, 93.279, 93.853, 93.865, 93.866, 93.867
CFDA Descriptions: Information not provided
Current Application Deadline: May 7th, 2020
Original Application Deadline: May 7th, 2020
Posted Date: December 21st, 2017
Creation Date: December 21st, 2017
Archive Date: June 12th, 2020
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: December 21st, 2017
Applicants Eligible for this Grant
Small businesses
Additional Information on Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-18-541.html
Grant Announcement Contact
NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
NIDCR Mentoring Network to Promote a Diverse Dental, Oral and Craniofacial Research Workfo...
Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparit...
Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Cl...
Building Interdisciplinary Research Careers in Women's Health (BIRCWH) (K12 Clinical Trial...
Epidemiological and Behavioral Research in Oral Health
Metagenomic Analyses of the Oral Microbiome
Phase Iii Clinical Trials in Oral Infectious Diseases
More Grants from the National Institutes of Health
Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical ...
Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
NINDS Program Project Grant (P01 Clinical Trial Optional)
Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial N...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com